Abstract

We have developed a tetracycline (tet)-off regulated expression of CD44s gene in the breast cancer (BC) cell line MCF-7 (B5 clone) and identified TGF-β2 (Transforming Growth Factor beta-2; 3 fold induction) as a potential CD44-downstream transcriptional target by microarray analysis. To further validate this finding, the same RNA samples, used for microarray analysis and their corresponding protein lysates, collected from the BC cell line MCF-7-B5, were examined for CD44 expression in the presence of HA. Our results showed that TGF-β2 mRNA levels were significantly elevated following the removal of tetracycline at 18, 24, and 48 h post-HA stimulation compared to the parental cells. Furthermore, the TGF-β2 precursor protein increased in a time-dependent pattern upon HA-stimulation and in the absence of tetracycline. More interestingly, inhibition of CD44 gene by RNAi method decreased TGF-β2 expression upon HA-stimulation, and subsequently inhibited BC cell invasion in vitro. In addition to identifying TGF-β2 as a target for HA/CD44 signaling, this data suggests that ATF/CREB might be a potential transcription factor linking HA/CD44 activation to TGF-β2 transcription and additional experiments are required for a better understanding of the molecular mechanisms underpinning the novel function of the CD44/ TGF-β2 signaling pathway in breast cancer metastasis.

Key words: Hyaluronan, CD44, TGF-β2, CRE/ATF, Tetracycline-inducible, Breast cancer, Metastasis, MCF-7-B5 clone

Introduction

BC is the most common cancer afflicting females worldwide. There are numerous risk factors involved, including but not limited to: early and extended hormonal exposure and the exposure to ionizing radiation, especially at early ages\(^1\). Metastasis is the most devastating aspect of tumor malignancy. Along with tumor formation, it is the primary cause of treatment failure and cancer-related death. BC cells metastasize mainly to the bone, liver, lung and the brain, but they also invade, and exfoliate into, body cavities, for example as malignant pleural effusions\(^3\). Although markers such as steroid receptor status, tumor size, nodal status and age at the time of diagnosis have been used for several years; none have demonstrated remarkable prognostic value\(^4\). Key to increasing the patient’s quality of life and long-term survival is to develop improved early detection methods and therapies for controlling cancer pro-
The current therapeutic measures used to treat cancer metastasis are limited in efficacy and also have multiple adverse effects stemming from their lack of specificity. As a crucial first step, we seek to gain an understanding of the unique disease processes associated with BC metastasis.

A crucial step involved in cancer cell metastasis requires the interaction of several classes of molecules between the tumor cell and the surrounding tissue including cell adhesion molecules. The major receptor for hyaluronic acid (HA), CD44, has been shown to initiate the metastatic spread of tumor cells. HA-CD44 interaction initiates a downstream cascade of events that modulate cell adhesion, motility, proliferation, and survival. However, the complete bi-molecular pathway of CD44 activation has not been elucidated. CD44 is the most studied alternatively-spliced gene in cancer and is associated with wide structural diversity. The standard form of CD44, CD44s, lacks the 10 variably spliced exons and codes for a typical type1 transmembrane protein. As a transmembrane matrix receptor with a cytoplasmic domain, CD44s has the basic structure to function in signal transduction. HA binding initiates extracellular clustering of CD44s, resulting in the activation of kinases. CD44s can serve as, a co-receptor physically linked to other classical signaling receptors, a docking protein for other proteins, and the trans-membrane domain of CD44s can be cleaved and translocated to the nucleus, where it functions as a transcription factor.

Although a number of studies have implicated CD44s in breast tumor invasion, the underlying mechanism is nascent. Nevertheless, recent studies carried out in our laboratory and others provide strong evidence, using both in vitro and in vivo models, that CD44s-mediated adhesion and signaling are required for cell growth and the dissemination of breast-derived tumors. In the present study we demonstrate a novel relationship between HA/CD44s signaling and the transcription of TGF-β2 in BC cells. To better understand the molecular mechanisms implicated in CD44s-mediated breast tumor invasion and metastasis, various molecular and functional techniques were used and TGF-β2, a CD44s-downstream transcriptional target gene was identified, which is involved in CD44-promoted BC cell motility.

Materials and Methods

Cells

The MCF7 and MDA-MB-231 breast cancer cell lines were purchased from American Type Culture Collection (Manassas, VA). All cells were cultured in DMEM media containing 10% (v/v) FBS, 2 mM L-glutamine and 1 mM sodium pyruvate (Gibco, Gaithersburg, MD). The MCF7-CD44 tet-off (MCF7-B5) BC cell line with regulated CD44s expression was maintained in DMEM supplemented with 10% fetal bovine serum, 2.5 µg/ml doxycycline (dox), 100 µg/ml G418 (Roche Diagnostics Ltd. (GmbH), Lewes, UK) and 1 µg/ml puromycin (5).

Chemicals and reagents

All chemicals were supplied by the Sigma Chemical Co. (St Louis, MO), unless otherwise stated. Hyaluronan of molecular weight 220 kDa and medical grade purity was purchased from Lifecore Biomedical Inc. (Chaska, MN).

Reverse Transcription Polymerase Chain Reaction (RT-PCR)

Total RNA was harvested from MCF7-B5 cells cultured in the presence (+dox) and absence (-dox) of dox following stimulation with 100 µg/ml HA (MW 220 kDa) for 18, 24, and 48 h using the Qiagen RNeasy Mini Kit (Cat no. 74104) as per manufacturer's instructions. For RT-PCR analysis, 1.0 µg of total RNA was reverse transcribed using standard reagents. Samples were incubated in the PTC-200 Thermal Cycler for reverse transcription at 50°C for 30 min. The initial PCR activation step at 95°C for 5 min was followed by 27 cycles. Each cycle consisted of 94°C for 30 seconds, 55°C for 30 seconds, and 68°C for 1 min. Final annealing was at 68°C for 10 min. The annealing temperatures for various genes were calculated according to their sequence and were optimized. The annealing temperatures and oligonucleotide primers used for CD44s, TGF-β2 and GAPDH genes are listed in Table 1. The PCR products were examined by electrophoresis in a 2% agarose gel, containing 0.2 µg/ml ethidium bromide.

| Genes    | Temperature | Oligonucleotide Primers                        |
|----------|-------------|------------------------------------------------|
| CD44     | 55°C        | TTT GCA TTG CAG TCA ACA GTC (sense)            |
|          |             | TTA CAC CCC AAT CTT CAT GTC CAC (antisense)    |
| TGF-β2   | 56°C        | GGA GGT TTA CAA AAT AGA CAT GCC (sense)        |
|          |             | AAG ACT CTG AAC TCT GCT TTC ACC (antisense)    |
| GAPDH    | 58°C        | ACC ACA GTC CAT GCC ATC AC (sense)             |
|          |             | TCC ACC ACC CTG TTG CTG TA (antisense)         |
Western-blot analysis

The CD44 expression in MCF7-B5 cells was induced by removal of dox at different time points, and protein lysates were collected as previously described (5). Protein lysates were collected centrifuged and the final concentration was determined using the Bicinchoninic Acid (BCA) protein assay reagent (Pierce, Rockford, IL). Protein samples (60 µg) were boiled for 5 minutes in an equal volume of reducing buffer (5 mmol/L of Tris/HCl (pH 7.4), 4% (w/v) sodium dodecyl sulfate, 20% (v/v) glycerol, 10% (v/v) mercaptoethanol, 0.2% (w/v) bromophenol blue), resolved on 12% polyacrylamide gels, and electroblotted onto a nitrocellulose membrane. The membrane was probed with mouse anti-human CD44s monoclonal antibody (1:500 dilution; R&D Systems,) and then treated with a sheep anti-mouse IgG/horseradish peroxidase conjugate (1:2000 dilution; Santa Cruz Biotechnology). The same samples were also examined for TGF-β2 using rabbit anti-human TGF-β2 polyclonal antibody (1:2000 dilution; Santa Cruz Biotechnology) and then treated with sheep anti-rabbit IgG/horseradish peroxidase conjugate (1:2000 dilution; Santa Cruz Biotechnology). Immunoreactivity was detected using chemiluminescence (Super signal, Pierce). Equal loading of protein samples was assessed by reprobing the membranes with β-tubulin antibody (1:2000 dilution; Sigma).

RNAi-mediated depletion of CD44s and TGF-β2

Oligonucleotides specific for human CD44 and TGF-β2, along with a Silencer® Negative Control siRNA were synthesized commercially (Ambion, TX) for siRNA inhibition of CD44 and TGF-β2. The sequences used to inhibit CD44 are, 5’-GGAAUUGG GCAUUUGGUAGTT-3’ (sense) and 5’-TTCCUUUAC CACGUAACACC-3’ (antisense), and for TGF-β2 are, 5’-CACUGUUAUGGACCAGUUTT-3’ (sense) and 5’-TTGUGAGCUAUACCUGGUCAA-3’ (antisense). Cells were seeded and grown to 50% confluency, washed twice with sterile PBS, then incubated at 37°C for 6 h, with a transfection cocktail comprising OPTI-MEM1, Lipofectamin-2000 (Invitrogen, NY) and the siRNA anti-CD44, anti-TGF-β2 or scrambled oligonucleotides at a final concentration of 100 nM or 200nM. After incubation, the media was replaced with 20% (v/v) FBS-enriched growth media, and subsequently incubated overnight at 37°C. Transfected cells were retransfected with CD44 siRNA transfection cocktail as described above. Protein lysates were harvested within 24h after the 2nd hit, and depletion of protein expression was confirmed by immunoblotting analysis.

Cell invasion assay

MCF7-B5 cells were cultured in the absence of (dox) and the presence of HA (100µg/ml) for a period of 24 hr for continuous induction of CD44 expression. Cells were treated with TGF-β2 specific siRNA, as described above, as inhibit TGF-β2 expression, and 24 hr later the cells were washed twice with sterile PBS and harvested by trypsinization. The harvested cells were then resuspended in DMEM supplemented with 0.5% BSA and plated in Millicell culture inserts (12 µm pore size, Millipore, MA), which were previously coated with a thin layer of 200 µg/ml of Matrigel™ (BD Biosciences, MA). The inserts containing the cells were placed into a tissue culture dish (lower chamber) with the “attracting medium” containing the MCF7-B5 special medium, supplemented with 100µg/ml of HA. Cells were incubated for 22h at 37°C and the Millicell culture insert was removed to allow wiping quickly the upper surface of the insert with a cotton swab in order to remove non-invasive cells. The cell culture inserts were dried under laminar flow hood for 4 h, and the cells that invaded and are present on the bottom of the filter were stained using the Diff-Quick staining kit, according to the manufacturers’ protocol (Dade Behring Inc.), and the stained cells were counted under a phase-contrast microscope, equipped with ocular grids.

Statistical analysis of data

Differences between data points in functional assays (invasion assay) were assessed for statistical significance by SPSS program using Student’s t-test two-tailed. Data was presented as Mean ± Standard deviation of at least triplicates from three experiments. The difference is considered statistically significant when p <0.05.

Results

In Vitro Characterization of the Tet Off-Regulated CD44s Expression System

We have previously generated a tet-off-regulated CD44s expression system in the parental MCF-7 cell line, expressing minimal amounts of CD44s to obtain an inducible MCF7-B5 BC cell line (10). To validate that this system functions properly in vitro, upregulation of both CD44s mRNA and protein was examined in the MCF7-B5 clone throughout a 48-h time course. Total RNA and protein lysates were collected from MCF7F-B5 cells at 18, 24, and 48 h in the presence and absence of dox and examined for CD44s expression by western blot. In the absence of dox, the level of expression of CD44s showed a time-dependent increase and was maintained up to
48 h. A single immunoreactive band was detected at a molecular mass equivalent to 85 kDa, which is consistent with the presence of CD44s (Fig. 1). However, in the presence of dox, the MCF7F-B5 cells cultured showed barely detectable CD44s expression, indicating that the tet-regulated CD44s suppression system was properly functional in the MCF7F-B5 cell line.

**Validation of TGF-β2 as a Transcriptional Target of CD44 Signaling**

The mechanisms responsible for upregulation and expression of the downstream target genes of CD44s-promoted metastasis in vivo are poorly understood. Therefore, we have used the tet off-regulated CD44s expression system in the MCF7-B5 cell line to identify novel transcriptional targets of HA/CD44s signaling. Microarray analysis led to the identification of a number of potential CD44s-downstream target genes\(^{10,19}\). Among these target genes, the microarray data obtained showed an upregulation of a 2.9-fold in TGF-β2 mRNA transcript levels, indicating that upon induction of CD44 in MCF7-B5 cells in the presence of dox, TGF-β2 mRNA expression increased by 2.9-fold\(^{10}\). TGF-β2 was chosen for further investigation on the basis that it is a growth factor that promotes BC metastasis, angiogenesis, and cytoskeletal remodeling\(^{22-21}\). Two strategies were employed to validate TGF-β2 as a potential downstream target of CD44s: i) Induction of CD44s upregulates TGF-β2: Time-course RT-PCR and western-blotting analyses were carried out on the same RNA and protein samples collected from MCF7-B5 used for microarray analyses. TGF-β2 RNA levels were significantly induced in the MCF7-B5 cells following the removal of dox at 18, 24, 48 h post-HA stimulation when compared to the MDA-231 cell lines (Fig. 2). Similarly, TGF-β2 protein was upregulated when CD44s expression was induced at different time points (Fig. 3); and ii) RNAi inhibition of CD44s downregulates TGF-β2: When the expression of CD44s was inhibited using the RNAi method, it showed that 24 h inhibition of CD44s was parallel to a significant decrease in TGF-β2 (Fig. 4).

**TGF-β2 underpins CD44 metastatic function in breast cancer cells**

The functional relevance of HA/CD44 induced TGF-β2 expression to BC cell invasiveness was investigated using the MCF7-B5 clone expressing CD44. Specific inhibition of CD44 expression by siRNA resulted in a specific decrease in TGF-β2 expression that correlated with a significant loss of BC cell invasiveness (data not shown). More interestingly, the invasiveness of MCF7-B5 cells post HA stimulation, was
significantly attenuated following RNAi-mediated reduction of TGF-β2 expression in these cells (Fig. 5). This reduction in invasiveness ability of MCF7-B5 transfected with specific anti-TGF-β2 RNAi was determined in comparison to cell controls, which were treated with scrambled RNAi, using t-test (Fig. 5).

![Figure 5. Functional validation of TGF-β2 expression in breast cancer cell line.](http://www.jcancer.org)

Discussion

Previous studies have indicated that HA/CD44s signaling plays an important role in BC metastasis. However, the signaling events that underpin HA/CD44s-promoted BC metastasis are poorly understood. The purpose of this study was to identify novel transcriptional targets of HA/CD44s signaling using a tetracycline-regulated (Tet-off) CD44s expression system in a weakly invasive BC cell line, MCF7F-B5, that normally expresses low or no endogenous CD44s. Following validation of the tet-regulated-CD44s expression system, RNA was extracted from HA-stimulated MCF7F-B5 cells and further examined by microarray analysis to identify possible downstream-transcriptional targets of HA/CD44s signaling. We have identified a number of potential downstream target genes and have previously validated Cortactin and Survivin as a target gene of CD44s-promoted breast tumor cell invasion. To better understand CD44 signal transduction mechanisms involved in breast tumor cell invasion and metastasis, the present study employed various molecular approaches to validate the transforming growth factor-β2, TGF-β2 (2.9 fold induction by microarray) as a novel potential CD44s-target mediating BC invasion. TGF-β2 belongs to a large family of polypeptide growth factors that is involved in regulating multiple biological processes including cell proliferation, angiogenesis, immune response, apoptosis, extracellular matrix synthesis, and differentiation. There are three isoforms of TGF, which are all secreted as latent precursor molecules. The latent forms of TGF are activated by proteolytic cleavage, pH changes, or interaction with integrins. The active forms of TGF bind to specific receptors, transmembrane serine/threonine kinases, which have been found to activate the SMAD signaling cascade. The study provided evidence that activation of TGF-beta2 is an essential CD44-downstream event required for tumor cell survival and metastasis. Furthermore, a polymorphism in the promoter of TGF-β2 that enhances expression of the protein was associated with lymph node metastasis in breast cancer patients, pointing to a role of TGF-β2 in the process of invasion.

Embryogenesis and metastasis share one common major obstacle that must be overcome by epithelial cells: survival following the detachment of the cell from the primary site and migration through the extracellular matrix. The process of epithelial-mesenchymal transition (EMT) enables epithelial cells to overcome these restrictions, paving the stage for physiologically programmed cell migration/invasion. Several studies have provided evidence that EMT plays an important role in cancer invasion and metastasis. During the process of EMT, cancer cells gain motility properties using developmental processes that involve reorganization of the actin cytoskeleton, and subsequently the formation of membrane protrusions required for the cell to invade. Takahashi et al (2010) have recently demonstrated that the hyaluronan-CD44-moesin complex associated with TGF-β receptor II and clathrin at actin microdomains, activated TGF-β signaling and caused both cell-cell dissociation and increased cellular motility through actin remodeling. Other studies have demonstrated that factors regulating developmental EMT, including the TGF-β signaling pathway, play roles in breast tumor progression. Also, activation of the TGF-β pathway in human cancer cell lines and in mouse tumor models can induce EMT and promote tumor cells to invade the ECM in culture and to metastasize to distant organs in mice.

Here, we provide evidence that TGF-β2 is a downstream transcriptional target of CD44-mediated MCF-7 cell invasion. The next question is how does CD44 induce the transcription of TGF-β2? CD44 can induce transcription of TGF-β2 via activation of the transcription factor cAMP response element-binding protein (CREB). Previous study showed that CD44...
can undergo sequential metalloprotease- and γ-secretase-mediated proteolytic cleavage, releasing the CD44 intracellular domain (CD44-ICD), which translocates to the nucleus and induce gene transcription[29]. In fact, recent study clearly demonstrated that the CD44-ICD protein translocated to the nucleus, bound to the transcription factor CREB, and increased S133 phosphorylation and CREB-mediated gene transcription[30], which is known to transactivate TGF-beta2[31]. It has been previously reported that a cAMP response element/activating transcription factor (CRE/ATF) site and an E-box motif are located within the TGF-beta2 gene promoter just upstream the transcription start site, and are essential for the transcription of the TGF-beta2 gene[31].

In conclusion, our results clearly show that TGFβ-2 was upregulated when CD44 was induced in the MCF-7B5 clone. Furthermore, inhibition of CD44 gene by RNAi method decreased TGF-beta2 expression upon HA-stimulation, and subsequently inhibited BC cell invasion in vitro. More interestingly, previous studies have demonstrated that overexpression of TGFβ-2 promotes invasion of various tumors, including ovarian cancer[32], melanoma[33], pancreatic cancer[34] and malignant epidermal keratinocytes[35]. Therefore, our data put together strongly suggest that TGFβ-2 is a potential downstream target gene mediating CD44s-promoted breast tumor cell invasion. Ongoing experiments in our laboratory using various experimental strategies are aiming to validate in vivo, the functional relevance of the CD44/CREB/TGFβ-2 signaling pathway in promoting breast tumour growth and metastasis.

Acknowledgement
This work was supported by His Majesty Sultan Qaboos University Strategic Grant SR/MED/GNET/10/01 (A.O.). We thank Dr. David J. Waugh for supplying the CD44-B5 clone.

Competing Interests
The authors have declared that no competing interest exists.

References
1. Ronckers CM, Erdmann CA, Land CE. Radiation and BC: a review of current evidence. Br Res 2005; 7:21-32.
2. Carmichael A, Sami AS, Dixon JM. BC risk among the survivors of atomic bomb and patients exposed to therapeutic ionizing radiation. Eur J Surg Oncol 2003; 29:475-9.
3. Shulman LN and Sugarbaker DJ. Malignant effusions. In: Harris JR, Lippman ME, Morrow M and Hellman S, eds. Diseases of the breast. Philadelphia: Lippincott-Raven. 1996: 833-840.
4. Berner HS, Suo Z, Risberg B, Villman K, Karlsson MG, Nesland JM. Clinicopathological associations of CD44 mRNA and protein expression in primary breast carcinomas. Histopathology 2006; 42:546-554.
5. Oshit A, Elmageed Z, Abdaboh M, Lice T, Raj M. In vivo Evidence for the Role of CD44 in Promoting BC Metastasis to the Liver. American Journal of Pathology 2007; 171: 2033-2039.
6. Liotta LA, Steeg PS, Stetler-Stevenson WG. Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation. Cell 1991; 64:327-336.
7. Toole BP. Hyaluronan: from extracellular glue to pericellular cue. Nature Reviews Cancer 2004; 4: 52-69.
8. Marhaba R and Zoller M. CD44 in Cancer Progression: Adhesion, Migration and Growth Regulation. Journal of Molecular Histology 2004; 35(3): 211-231.
9. Bajorath J. Molecular organisation, structural features, and ligand binding characteristics of CD44, a highly variable cell surface glycoprotein with multiple functions. Proteins 2000; 39:103-111.
10. Hill A, McFarlane S, Mulligan K, et al. Contactin underpins CD44-promoted invasion and adhesion of BC cells to bone marrow endothelial cells. Oncogene 2006; 25:6079-91.
11. Naor D, Sionov RV, Ish-Shalom D. CD44: structure, function, and association with the malignant process. Adv Cancer Res 1997; 71:241-319.
12. Ito T, Williams JD, Fraser DJ, Phillips AO. Hyaluronan regulates transforming growth factor-β1 receptor compartmentalization. J Biol Chem 2004; 279: 25326-25332.
13. Lesley J and Hyman R. CD44 structure and function. Front Biosci 1998; 3c:70-630.
14. Lopez JI, Camenisch TD, Stevens MV, Sands BJ, McDonald J, Schroeder JA. CD44 attenuates metastatic invasion during BC progression. Cancer Res 2005; 65:6755-63.
15. Mori H, Tomari T, Koshikawa N, et al. CD44 directs membrane-type 1 matrix metalloproteinase to lamellipodia by associating with its hemopexin-like domain. EMBO J 2002; 21: 3949-3959.
16. Murai T, Miyazaki Y, Nishinakamura H, et al. Engagement of CD44 promotes Rac activation and CD44 cleavage during tumor cell migration. J Biol Chem 2004; 279: 4541-4550.
17. Murakami D, Okamoto I, Nagano O, et al. Presenilin-dependent γ-secretase activity mediates the intramembranous cleavage of CD44. Oncogene 2003; 22: 1511-1536.
18. Oshit A, Matrougui K, Bengrine A, Koochekpour S, Zerfaoui M, Yousief Z. Survivin is Not only a Death Encounter but a Survival Protein for Invasive Breast Cancer. Cancer Res 2003; 63:8004-8008.
19. Ohtani K, Nakamura D, Itoh T, et al. CD44 proteolysis increases TGFβ1 inhibitor AP 12009 in clinical development against malignant tumors. Recent Results Cancer Research 2008; 177: 137-50.
20. Bourquin-Lyon L, Singleton PA, Zhu H, Zhou B. Hyaluronan promotes signalng interaction between CD44 and the transforming growth factor beta receptor I in metastatic breast tumor cells. J Biol Chem 2002; 277:39703-12.
21. Buck MB, Fritz P, Dippon J, Zugmaier G, Knabbe C. Prognostic Significance of Transforming Growth Factor B Receptor II in Estrogen Receptor-Negative BC Patients. Clinical Cancer Research 2004; 10: 491-8.
22. Huang S, Huang J. TGF-beta Control of Cell Proliferation. Journal of Cellular Biochemistry 2005; 96: 447-462.
23. Schlingensiepen KH, Fischer-Blass B, Schmaus S, Ludwig S. Antisense therapeutics for tumor treatment: the TGFβ-2 inhibitor AP 12009 in clinical development against malignant tumors. Recent Results Cancer Research 2006; 177: 137-50.
24. Bourquin-Lyon L, Singleton PA, Zhu H, Zhou B. Hyaluronan promotes signaling interaction between CD44 and the transforming growth factor beta receptor I in metastatic breast tumor cells. J Biol Chem 2002; 277:39703-12.
25. Buck MB, Knabbe C. TGF-β signaling in breast cancer. Ann N Y Acad Sci 2006; 1089: 119.
26. Takahashi E, Nagano O, Ishimoto T, et al. Tumor necrosis factor-alpha regulates transforming growth factor-beta-dependent epithelial-mesenchymal transition by promoting hyaluronan-CD44-moesin interaction. J Biol Chem 2010; 285: 4060-73.
27. Zhang J, Liang Q, Lei Y, et al. SON4 Induces Epithelial-Mesenchymal Transition and Contributions to Breast Cancer Progression. Cancer Res 2012; 72: 4597-608.
28. Oht M, Heider KH, Beug H. TGFbeta signaling is necessary for carcinoma cell invasiveness and metastasis. Curr Biol 1998; 8: 1243-52.
29. Janda E, Lehmann K, Killisch I, et al. Ras and TGF[beta] cooperatively regulate epithelial cell plasticity and metastasis: dissection of Ras signaling pathways. J Cell Biol 2002; 156: 299-313.
30. Okamoto I, Kawano Y, Murakami D, et al. Protoeolytic release of CD44 intracellular domain and its role in the CD44 signaling pathway. J Cell Biol 2001; 155: 735-62.
element-binding protein (CREB) and activating transcription factor-1 (ATF-1) is modulated by protein kinases and the coactivators p300 and CREB-binding protein. *J Biol Chem* 1999; 274:34020-8.

32. Do TV, Kubbs LA, Du H, Sturgis CD, Woodruff TK. Transforming growth factor-beta1, transforming growth factor-beta2, and transforming growth factor-beta3 enhance ovarian cancer metastatic potential by inducing a Smad3-dependent epithelial-to-mesenchymal transition. *Mol Cancer Research* 2008; 6:695-705.

33. Zhang C, Zhang F, Tsan R, Fidler II. Transforming growth factor-beta2 is a molecular determinant for site-specific melanoma metastasis in the brain. *Cancer Res* 2009; 69:828-35.

34. Hilbig A, Oettle H. Transforming growth factor beta in pancreatic cancer. *Curr Pharm Biotechnol* 2011; 12(12): 2158-64.

35. Davies M, Prime SB, Eveson JW, Price N, Ganapathy A, D’Mello A, Paterson IC. Transforming growth factor-beta enhances invasion and metastasis in Ras-transfected human malignant epidermal keratinocytes. *Int J Exp Pathol* 2012; 93(2): 148-56.